Search PubMed⌕ Search

PubMed · 15532141

Preventing medication errors.

Abstract

(1) 319 adverse effects due to errors occurring during the drug use process, as well as errors spotted before any incident, were collated in French hospitals in 2000-2001 and characterised for their type, cause, contributing factors, and consequences. (2) All stages of the drug use process were implicated in errors: prescription, transcription, preparation, dispensing, administration, and drug monitoring. (3) Dosing errors (often overdose) were the most common. (4) The main causes were poor practices and inadequate knowledge, followed by problems of communication, packaging and confusion over drug names. (5) Contributing factors included failure to follow rules and procedures, inadequate communication or training, interruptions and distractions, and drug storage on the wards. (6) The prevention of adverse effects linked to drug errors requires a commitment to record all problems, analyse them in depth, and enforce safe working practices for all health professionals.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

2004. Preventing medication errors.. https://pubmed.ncbi.nlm.nih.gov/15532141/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process.

The approval of new human pharmaceutical products in the EU requires an assessment of potential environmental risks related to the use by patients, besides the evaluation of the human safety, efficacy, and quality evaluation. The current guidance by the European Medicines Agency (EMEA), describing the process of the environmental risk assessment for human drugs, covers a two-tiered assessment programme with a modelling step for an environmental exposure scenario and a subsequent step of environmental fate and effects testing. The following paper describes ways how the requirements of the environmental risk assessment can be sensibly incorporated in the overall approval process of a pharmaceutical product including the risk/benefit analysis for the patient. The resources for environmental testing and assessment programmes can be employed economically, if the pharmacological, toxicological, and pharmacokinetic information obtained during the development programme of a human pharmaceutical is used to develop substance-specific test programmes and to evaluate the environmental risk assessment taking into account the pharmacodynamic properties and the use pattern by patients. Finally, we suggest that the environmental risk evaluation process as part of drug approvals should adhere to a focussed assessment strategy considering existing knowledge and the therapeutic needs.

Drug-Related Side Effects and Adverse Reactions↗